“The sequence of disease-modifying therapies in RMS:safety & immunologic considerations”
Gabriel Pardo MD Director, OMRF Multiple Sclerosis Center of Excellence Associate, Member OMRF Arthritis and Clinical Immunology Research Program, Oklahoma City, USA